| 5.02 -0.41 (-7.55%) | 05-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.84 | 1-year : | 10.54 |
| Resists | First : | 6.71 | Second : | 9.02 |
| Pivot price | 7.07 |
|||
| Supports | First : | 2.98 | Second : | 2.47 |
| MAs | MA(5) : | 5.89 |
MA(20) : | 6.55  |
| MA(100) : | 6.9 |
MA(250) : | 27.78 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 26.6 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 80.09 | Low : | 2.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPRC ] has closed above bottom band by 7.1%. Bollinger Bands are 15.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.42 - 5.46 | 5.46 - 5.49 |
| Low: | 4.93 - 4.97 | 4.97 - 5.01 |
| Close: | 4.95 - 5.02 | 5.02 - 5.07 |
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Tue, 12 May 2026
Number of shareholders of SciSparc Ltd. – NASDAQ:SPRC - TradingView
Mon, 11 May 2026
SciSparc (NASDAQ: SPRC) regains Nasdaq compliance but faces future test - Stock Titan
Fri, 06 Mar 2026
Neurothera Labs Signs Non-Binding Term Sheet to Acquire - SEC.gov - SEC.gov
Mon, 02 Mar 2026
SciSparc to cut outstanding shares to about 565K on Mar. 4 - Stock Titan
Mon, 02 Mar 2026
SciSparc Announces 1-for-9 Reverse Share Split - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 565500 (%) |
| Held by Institutions | 47100 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.03e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 156.52 |
| Profit Margin | 0 % |
| Operating Margin | -569.6 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.31e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 225.19 |
| EBITDA (p.s.) | 404800 |
| Qtrly Earnings Growth | 3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.03 |
| Price to Sales | 0.02 |
| Price to Cash Flow | 0 |
| Dividend | 30800 |
| Forward Dividend | 84390 |
| Dividend Yield | 613546% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|